Aarti Pharmalabs Limited has informed the Exchange about General Updates
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs has filed its Business Responsibility and Sustainability Report (BRSR) for FY 2024-25 with BSE and NSE, as required under SEBI's Listing Regulations. The company manufactures Active Pharmaceutical Ingredients (APIs), intermediates, and xanthine derivatives, reporting a turnover of around ₹1,771 crore, net worth of ₹1,844 crore, and exports making up about 57% of revenue across 64 countries. It runs 15 plants (including 3 R&D centres) in India and employed 1,732 permanent employees and 1,273 workers as of March 2025, with women representing 33% of the 12-member board. The company has voluntarily undertaken third-party BRSR Core assurance from SustainEDGE and aligned with standards such as ISO 9001, ISO 14001, ISO 45001, FDA, GMP, SBTi, EcoVadis, CDP, and SEDEX/SMETA. On ESG investments, R&D spending on environmental/social improvements rose sharply to 36.23% (from 7.35%), and capex on such improvements increased to 23.74% (from 8.04%). A ₹2.5 lakh bank guarantee penalty from the Gujarat Pollution Control Board was issued but the closure directions were later revoked, and the company spent ₹4.31 crore on CSR during the year.
This is a routine regulatory disclosure rather than a business-altering announcement, so it should not move the stock on its own. However, it shows improving ESG metrics — higher environmental R&D and capex, zero workplace fatalities, and voluntary sustainability assurance — which may appeal to ESG-focused investors.